These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12125628)

  • 21. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
    Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J
    J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086
    [No Abstract]   [Full Text] [Related]  

  • 22. Some competition for 1592.
    GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switch to efavirenz in a protease inhibitor-containing regimen.
    Knechten H; Stürner KH; Höhn C; Braun P
    HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
    [No Abstract]   [Full Text] [Related]  

  • 26. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
    Caso JA; Prieto Jde M; Casas E; Sanz J
    AIDS; 2001 Jul; 15(11):1447-8. PubMed ID: 11504970
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
    Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
    AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
    [No Abstract]   [Full Text] [Related]  

  • 28. Substitution for protease inhibitors in HIV therapy.
    Hirschel B
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14681514
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.
    Caro JJ; O'Brien JA; Migliaccio-Walle K; Raggio G
    Pharmacoeconomics; 2001 Jan; 19(1):95-104. PubMed ID: 11252549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using ritonavir with indinavir in cases of virologic failure.
    TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-HIV agents. Indinavir--3 years and still going strong.
    TreatmentUpdate; 2000 Sep; 12(6):3-4. PubMed ID: 12132460
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
    Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on antivirals.
    Proj Inf Perspect; 1997 Nov; (23):8-11. PubMed ID: 11365381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression.
    Holmberg SD; Hamburger ME; Moorman AC; Wood KC; Palella FJ;
    Clin Infect Dis; 2003 Sep; 37(5):702-7. PubMed ID: 12942404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nevirapine found to be as effective as efavirenz.
    TreatmentUpdate; 2003; 15(2):3-4. PubMed ID: 12693360
    [No Abstract]   [Full Text] [Related]  

  • 37. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Mata R; Gómez-Vera J; Alarcón A; Pachón J
    J Acquir Immune Defic Syndr; 2003 Feb; 32(2):240-2. PubMed ID: 12571537
    [No Abstract]   [Full Text] [Related]  

  • 38. Swiss study switching to efavirenz.
    TreatmentUpdate; 2002 Feb; 14(2):1-2. PubMed ID: 12691037
    [No Abstract]   [Full Text] [Related]  

  • 39. Efavirenz (SUSTIVA, formerly DMP-266) 48-week data announced.
    AIDS Treat News; 1997 Sep; (No 279):2-3. PubMed ID: 11364690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.